- REM-422 granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of ACC and AML - Advances REM-422, an oral small molecule messenger RNA (mRNA) degrader to ...
Remix Therapeutics has enrolled and dosed the first subjects in two Phase I clinical trials of REM-422, a treatment candidate for two types of cancer. The trials target recurrent or metastatic adenoid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results